The 10 facts about dustarlimab and eliminating cancer in 6 months
 |
| Eliminate Cancer in 6 Months with Dostarlimab drug |
In a clinical trial conducted by the US-based Memorial Sloan Kettering Cancer Center in 2022 and 18 patients with rectal cancer discovered that the cancerous tumors disappeared within 6 months after receiving the experimental drug Dostarlimab, which was described for the first time in history as a potential treatment for cancer, gave hope to cancer patients around the world that a definitive cure for this dreaded disease would be found.
Here are 10 facts you should know about Dostarlimab:
1- What is dostarlimab
is an immunotherapy drug sold under the trade name (Jimperil) that was approved for medical use in the United States and the European Union in April 2021 by the U.S. Food and Drug Administration as a treatment for endometrial cancer and is an effective treatment for solid evolving deficiencies in mismatch repair (DMMR).
 |
| Anticancer Jemperil (Dostarlimab) |
2- How dostarlimab works
this immune drug contains molecules that have been produced in the laboratory in the form of monoclonal antibodies (Monoclonal Antibody Drug) and acts as alternative antibodies in the body as this drug stops the work of cancer-causing cells and detects them, which helps the immune system to recognize These cells and tissues work against them.
3- History of dustarlimab
The rectal cancer study and the trial of dustarlimab were inspired by a clinical trial conducted by Dr. Luis Diaz Jr., an oncologist at Memorial Sloan Kettering Cancer Center, in 2017. He recently commented, according to The Independent, after this clinical trial of Dustarlimab This is the first time "this has happened in the history of cancer."
4- Who has been clinically tested dostarlimab
The clinical trial included 18 patients with rectal cancer. In all patients, the rectal cancer was of an advanced type, which means that the tumors had spread within the rectum, and in some cases to the lymph nodes but not to other organs.
.jpg) |
| Dostarlimab clinical trial |
5- HOW TO USE Dustarlimab
Dustarlimab is in the form of a liquid (solution) that is injected slowly into a vein for more than 30 minutes. The drug is given once every three weeks for four cycles, then once every six weeks according to the doctor's recommendations. The doctor may stop treatment with dostarlimab temporarily or permanently according to the patient's response to the drug and side effects. Only patients who have a hereditary feature of mismatch repair deficiency (DMMR) can receive treatment with this drug.
 |
| Dostarlimab intravenous injection |
6- How were the results of the trial of dustarlimab
At the end of the trial, the cancer was examined through physical examination or endoscopy, CT scan, and magnetic resonance and it showed all Patients had a complete clinical response after the trial period with no signs of tumor, followed by chemotherapy and radiotherapy sessions.
7- What are the side effects of dustarlimab
The most common side effects of dustarlimab include fatigue, nausea, vomiting, joint and chest pain, itching, or fever, anemia, diarrhea, and constipation. Dustarlimab may cause problems with the hormonal glands (such as the thyroid gland, pituitary gland, adrenal gland, and pancreas.) The doctor may prescribe another medicine to help treat the side effects of this medicine. The patients also showed a complete absence of major complications after treatment, as well as any signs of cancer recurrence in patients up to 25 months after the end of the clinical trial.
8- Who should not receive dustarlimab
following cases are incompatible with this medicine. See your doctor if you have any of the following:
- Hyperthyroidism
- A condition with low thyroid hormone levels
- Type 1 diabetes
- Severely decreased function of the adrenal cortex
- A type of lung inflammation called interstitial pneumonitis
- Large intestine
- inflammation Hepatitis called hepatitis
- Inflammation Kidney
- High blood sugar
- Pregnancy
- a patient who produces milk and is breastfeeding
- Hypophysis
9- What are the precautions before using dustarlimab
Before using this medicine, the doctor should be informed if the patient suffers from any kind of allergies, as well as the patient’s medical history in addition to all the medicines used. The patient may need to tell the doctor if she is pregnant or planning to become pregnant. Birth control is required while using this medication for 4 months.
10- What is the company that produces dostarlimb and what is its cost
The study was sponsored by GlaxoSmithKline Pharmaceutical Industries, which will manufacture and produce it. The estimated cost of dostarlimab, according to the New York Times, is about $11,000 per dose. The cost of 8 doses reaches 8800 thousand dollars.
 |
| Dostarlimab FDA approval GlaxoSmithKline |
References
Written by: Dr. Amira Saleh
Comments
Post a Comment